Risks and Concerns with Compounded Semaglutide Lack of FDA Approval and Quality Control One of the primary arguments against compounded Semaglutide products is the FDAs lack of supervision when it comes to making them
They had a baseline glycated hemoglobin (HbA1c) level between 7.5% and 10.5% (58-91 mmol/mol), a body-mass index of 25 kg/m2 or greater, and established cardiovascular disease or a high risk of cardiovascular events
oleifera exhibits a preventive function versus induced ROS in vitro (520, 521)
signs of bowel obstruction (severe abdominal distension, absence of stool/gas, vomiting)
Diagnosis and management of the metabolic syndrome in obesity
Torreele, E., Van Der Sluiszen, A